Oxford Immunotec, a commercial-stage diagnostics company providing advanced immunology tests, priced its IPO at $12 per share and went public on Friday. The company trades on the NASDAQ under the symbol OXFD. Oxford Immunotec has raised about $121 million in VC funding to date, including a $40 million Series C—its largest single round—in 2007. Backers include Clarus Ventures (24.3% pre-IPO stake), New Leaf Venture Partners (13%) and DFJ Esprit (10.1%), among others. The company's shares ended their first day of trading at $15.40, up 28.33%.